node – Oral Cancer News

Sentinel node biopsy makes case in oral cavity cancer

Source: www.medpagetoday.com Author: Charles Bankhead Patients with early-stage oral cavity cancers had similar survival with less neck disability with a less invasive approach to lymph node assessment, a multicenter randomized study showed. The 3-year overall survival (OS) rate was 87.9% with sentinel lymph node biopsy (SLNB) and 86.6% with elective node dissection (ND). The 3-year disease-free survival (DFS) rate was 78.7% versus 81.3% in the SLNB and ND groups. Both outcomes met statistical criteria for noninferiority of the two approaches to lymph node assessment. The SLNB group had significantly better scores on a test of neck function, reported Yasuhisa Hasegawa, MD, PhD, of Asahi University Hospital in Gifu, Japan, and co-authors. "SLNB-navigated ND is noninferior and less invasive than elective ND," the authors wrote in the paper online in the Journal of Clinical Oncology. "The results of this study may promote a widespread use of SLNB (for early-stage OCSCC [oral-cavity squamous cell carcinoma]) worldwide." The results added to a growing volume of evidence suggesting similar outcomes between SLNB and the more-invasive ND. Last year a randomized study from France showed a 2-year relapse-free survival rate of 89-91% with the two approaches to lymph node assessment in oral and oropharyngeal cancer. A large retrospective cohort study resulted in similar OS and a shorter hospital stay as compared with ND. Multiple studies have demonstrated improved functional outcomes and lower complication rates with SLNB, the authors noted. Optimal management of clinically node-negative early-stage OCSCC remains controversial. Advantages have been reported for observation, ND, [...]

Oral Cancer Foundation News Team - A2021-04-27T06:01:14-07:00April, 2021|Oral Cancer News|

Tiny cancer tracers could boost survival rates

Source: www.bignewsnetwork.com/ Author: PanArmenian.Net staff Nanoparticles that can detect complex cancer cells and potentially improve five-year survival rates are headed for human trials. South Australian company Ferronova has developed the nanoparticles that are designed to identify early stage tumor and related cancer cells, Medical Xpress says. Ferronova Chief Executive Stewart Bartlett said the tiny cancer tracers were expected to be trialled on oral cancer patients at the Royal Adelaide Hospital in April 2020, pending key approvals. Bartlett said once Ferronova's polymer-coated iron oxide nanoparticles were injected into patients they would show up on an MRI within about 15 minutes. 'The way they work in cancer is they're designed to be detected around a solid tumor' he said. 'They'll actually be picked up by your lymphatic system as a foreign body and follow the same pathway as any cancer spread from a primary tumor would follow. 'If you can actually know where those particles are going you can also determine where the cancer would have gone.' Ferronova was spun out of a nanoparticles research collaboration between the University of South Australia and New Zealand's Victoria University, with backing from IP investors Powerhouse Ventures and UniSA Ventures. Bartlett said preclinical trials at the Mawson Lakes lab had given the company confidence to use the particles on humans. He said the treatment was expected to be 90 percent accurate. 'We've added a molecule to the particles so they go to the first lymph node and they are retained in the first lymph node, [...]

Oral Cancer Foundation News Team - A2019-11-03T10:29:59-07:00November, 2019|Oral Cancer News|

PET-FDG improves staging, management of head, neck cancer

Source: helathimaging.com Author: staff Adding whole-body PET-FDG to the pre-therapeutic conventional staging of head and neck squamous cell carcinoma improved the TNM [tumor, node and metastasis] classification of the disease and altered the management of 13.7 percent of patients, according to a study published in the February issue of the Journal of Clinical Oncology. Max Lonneux, MD, from the departments of nuclear medicine, head and neck surgery, radiation oncology and maxillofacial surgery, Cliniques Universitaires Saint-Luc in Brussels, and colleagues included his 233 patients in this multicenter, prospective study with newly diagnosed and untreated head and neck squamous cell carcinoma. Researchers first determined the TNM stage and therapeutic decision based on the conventional work-up (including physical exam, CT/MRI of the head and neck region, and thoracic CT) and sealed in envelope. They then performed whole-body PET-FDG, and subsequently wrote TNM stage and therapeutic decision in a sealed envelope. The investigators also recorded changes in TNM stages and in patient management as a result of PET-FDG imaging. Clinical outcome and histopathology were used as gold standards to validate the TNM stage. Conventional and PET stages were compared using the McNemar test. According to the authors, conventional and PET stages were discordant in 43 percent of the patients. PET proved to be accurate in 47 patients and inaccurate in 13 patients. TNM status was left unconfirmed in 40 patients because no therapeutic change was expected from the stage difference. The researchers found that conventional plus PET TNM classification (envelope two) was significantly more [...]

Oral Cancer Foundation News Team - A2010-02-17T08:18:31-07:00February, 2010|Oral Cancer News|